Application of PD-L1 inhibitors in the treatment of non-small cell lung cancer

VernacularTitle:PD-L1抑制剂在非小细胞肺癌中的应用
Author: Hongxia XIE ¹ ; Jinhui ZUO ; Dongying LIAO ; Renfen DENG ; Yang YAO ; Yingjie JIA ; Xiaojiang LI ; Fanming KONG
Author Information

1. 天津中医药大学第一附属医院肿瘤科　国家中医针灸临床医学研究中心，天津　300382
Keywords: Lung neoplasms; Immunotherapy; PD-L1
From: Journal of International Oncology 2022;49(2):111-115
CountryChina
Language:Chinese
Abstract: Patients with non-small cell lung cancer (NSCLC) are treated in a variety of ways. In addition to radiotherapy, chemotherapy and targeted therapy, breakthroughs have been made in immune checkpoint inhibitors, in particular, programmed cell death 1 (PD-1) and its ligand (PD-L1) inhibitors have achieved survival benefits for NSCLC patients, and some of them have been approved as first-line drugs by the US Food and Drug Administration. Currently, commonly used PD-L1 inhibitors are atezolizumab, durvalumab and avelumab. Combination therapies include combination with chemotherapy, anti-vascular endothelial growth factor drugs, molecular targeted therapy and immunotherapy.